Show simple item record

dc.contributor.authorSax, Michael
dc.contributor.authorPlummer, Prue
dc.contributor.authorMittal, Vivek
dc.contributor.authorMellick, Albert
dc.date.accessioned2017-05-03T13:47:07Z
dc.date.available2017-05-03T13:47:07Z
dc.date.issued2014
dc.identifier.issn0311-306X
dc.identifier.urihttp://hdl.handle.net/10072/69892
dc.description.abstractIt has been 40 years since Folkman's seminal paper [Cancer Res 1974. 34:2109-13], proposing the presence of a tumour associated angiogenic factor, which could be targeted as an anticancer therapy. There are currently a handful of drugs in trial or use that have been marketed as targeting angiogenesis. Unfortunately, the most widely used of these, bevacizumab (Avastin鬠Roche), has met with limited success clinically. For this reason and based on a calculation of cost benefit, bevacizumab is now only publically subsidised for use in a limited range of solid tumours. That the contribution of vasculature to malignancy remains poorly understood is increasingly clear. At the same time, the traditional view that vascularisation is a passive participant in the process of malignancy, and that endothelium merely provides a conduit by which tumour cells spread, is being replaced with an understanding that vasculature is a key player in the process of metastasis. Furthermore, the identification of non-traditional sources of vasculature has complicated our understanding of the tumour endothelium as a unique population that can be simply targeted as an anticancer therapy. The following review seeks to provide an up-to-date view of vascular contribution to metastasis and implications for new vasculature-targeted anticancer treatments.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherCancer Council Australia
dc.publisher.placeAustralia
dc.publisher.urihttps://www.cancer.org.au/health-professionals/resources/cancer-forum
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom103
dc.relation.ispartofpageto107
dc.relation.ispartofissue2
dc.relation.ispartofjournalCancer Forum
dc.relation.ispartofvolume38
dc.rights.retentionY
dc.subject.fieldofresearchOncology and Carcinogenesis not elsewhere classified
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode111299
dc.subject.fieldofresearchcode1112
dc.subject.fieldofresearchcode1117
dc.titleVascular contribution to metastasis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.hasfulltextNo Full Text
gro.griffith.authorMellick, Albert S.
gro.griffith.authorSax, Michael


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record